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Abstract 
 
Megakaryocytes (MKs) derive from haematopoietic stem cells (HSCs) by a 
process called megakaryopoiesis. One of the main functions of MK is the production of 
platelets. Immune thrombocytopenia (ITP) is defined as a reduction in the platelet count 
below 100 x 109/L in peripheral blood in the absence of a clear cause. It has been 
suggested that T cells are primed against MK. Our aim is to determine whether plasma of 
ITP patients alters characteristics of megakaryopoiesis including terminal development 
and expression of immune markers including PD-L1 (CD274) and HLA-DR.  
CD34+ HSC were cultured for 10 days to differentiate them into MKs. At day 7, 
plasma from 3 healthy donor and 4 ITP patients were added. Study of expression of 
CD34, CD38, CD41, CD42b, CD274 and HLA-DR was performed with flow cytometry. 
Confocal microscopy was performed to confirm the expression of PD-L1 throughout the 
development. 
Culturing the cells with healthy control plasma resulted in significantly higher 
number of CD42+CD41+CD38+ cells, as well as significant lower expression of HLA-DR 
compared to medium only and ITP patients’ plasma. . In contrast, MKs cultured in plasma 
from patients with ITP had a higher HLA-DR expression than MKs cultured in healthy 
plasma, demonstrating an important role for plasma derived factors to alter immune 
regulatory potential for MKs and platelets. PD-L1 expression was positive throughout the 
development but it did not change significantly with the co-culture with either healthy 
control or ITP patients’ plasma, compared to medium only.  
MKP and mature MK can express PD-L1 in vitro culture. Also, healthy plasma 
and ITP plasma has the potential to enhance megakaryopoiesis. 
 
Key words: Megakaryocytes, ITP, CD274, PD-L1, HLA-DR. 
 
Word count: 8540 
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Chapter I. Introduction 
 
I.1 Megakaryocytes  
 
It is important to clarify that our understanding of the developmental process has 
multiple gaps and, a substantial amount of our knowledge derives from research in murine 
models, which does not apply necessarily to humans (Gabdoulline et al., 2015; Pera & 
Trounson, 2004; Woolthuis & Park, 2016). Nevertheless, the most spread model 
conceives the hierarchical concept based on  HSCs’ loss of self-renewal and pluripotency 
(Woolthuis & Park, 2016).   
 
The classical model description starts with the loss of self-renewal capacity in 
HSCs to give rise to multipotent progenitors (MPPs), which maintain pluripotency. 
Further differentiation will provide cells with a restricted lineage potential, known as 
common myeloid progenitor (CMP) and common lymphoid progenitor (CLP). CMPs are 
accountable for megakaryocytes/erythrocytes progenitors (MEP), 
granulocytes/macrophages progenitors (GMP) and dendritic cell (DC) progenitors. On 
the other hand, CLP are responsible for T cell progenitors, B cell progenitors, NK cell 
progenitors and DC progenitors (Mosaad, 2014; Woolthuis & Park, 2016) (Figure 1). 
 
The model for megakaryopoiesis is a work in progress. In recent years, some 
murine studies have shown the presence of new progenitor populations and, an 
unexpected wide differentiation capacity in them. This progress in the model of MKs 
differentiation has been based on the characterisation of multiple markers: Lin Sca-1 c-
kit (LSK), CD34, CD38, CD41, CD42b, CD61, CD110, von Willebrand factor (vWF) 
and FMS-like tyrosine kinase 3 (Flt3)(Adolfsson et al., 2001, 2005; Woolthuis & Park, 
2016; Yang et al., 2005). A brief description of those markers is given in Table 1 (Furness 
& McNagny, 2006; Levis & Small, 2003; J. Li, Xia, & Kuter, 2000; Shrimp et al., 2014; 
Zwicker, Lacroix, Dignat-george, Furie, & Furie, 2012). 
 
In the 1990s, several studies were done in mice to identify markers for the most 
primitive progenitor in haematopoiesis. By the end of the decade, the recognition of Lin-
Sca-1+c-kit+CD34- (LSKCD34-) as long-term HSCs (LT-HSCs) and Lin-Sca-1+c-
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kit+CD34+ (LSKCD34+) as short-term HSCs (ST-HSCs) was established for the murine 
model (Nakauchi, Takano, Ema, & Osawa, 1999; Sato, Laver, & Ogawa, 1999). 
 
 
 
Figure 1. Classical model of differentiation of HSC. It describes the versatility of a pluripotent HSC to 
produce most lineages’ progenitors in a 5 stages hierarchical structure.    
 
The characterisation of human HSC’s surface markers took longer. Since the 
1960s, CD34 was considered as a reliable marker for HSCs in the bone marrow. Cells 
with surface expression of CD34 show high capacity for differentiation into multiple 
lineages (Krause, Fackler, Civin, & May, 1996). Furthermore, its presence conjointly 
with other markers, allow to establish an early progenitor, because as development 
progresses, CD34 is downregulated (Mosaad, 2014). However, Goodell et al, developed 
an experiment based in Hoechst dye efflux activity, and identified that some CD34- cells 
were HSCs, establishing them as long-term culture initiating cells. Also, they 
demonstrated that these cells were the responsible to give rise to CD34+ (Goodell et al., 
1997; Guo, Lubbert, & Engelhardt, 2003). 
 
Later, Adolfsson et al. revealed that the loss of self-renewal in LT-HSCs matched 
the upregulation of Flt3 (Adolfsson et al., 2001). This finding turned out to be relevant in 
the description of cells throughout their differentiation, since, to a certain extent, the 
regulation of Flt3 is predictive of lineage predilection (Woolthuis & Park, 2016). 
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A descriptive study in mice, based on the regulation and CD34- fraction of Lin-
Sca-1+c-Kit+ cells presented a preference in LSKCD34-Flt3- and LSKCD34+Flt3- towards 
MK development. On the other hand, LSKCD34+Flt3hi cells exhibited a limited capacity 
to differentiate into MEP (Adolfsson et al., 2005; Woolthuis & Park, 2016) (Figure 2). 
 
MKs and erythrocytes rise from a common progenitor, hence it is important to 
remark that further differentiation into MK will require the interaction of two 
transcription factors: Friend-leukaemia integration 1 (FLI-1) and Runt related 
transcription factor 1 (RUNX-1) (Eto & Kunishima 2016; Okada et al. 2013). Even 
though, FLI-1 is a crucial actor, it seems that it has an inevitable dependency of RUNX-
1 to inhibit the dephosphorylation of serine 10 (Draper et al., 2016; Huang et al., 2009; 
Okada et al., 2013). Additionally, RUNX-1 blocks Krueppel-like factor 1 (KLF-1), the 
erythroid master regulator, leaning the balance towards FLI-1 and, therefore, MK 
differentiation (Kuvardina et al., 2015). Additionally, the gene DLX4 has shown 
predilection for MK differentiation. According to Trinh et al., using gene set enrichment 
analysis, DLX4 seems to induce shift towards independent MK gene sets. They showed 
evidence of DLX4 upregulating IL-1β through activation of NF-κβ (Trinh et al., 2015) 
(Figure 3). 
 
Table 1. Surface markers in HSCs and MKs.  
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Figure 4 shows differentiation pathway and expression of surface markers. During 
the final stage of platelets production, endomitosis starts, which implies the accumulation 
of DNA content in a single polylobulated nucleus without cytokinesis (polyploidization). 
This process requires the down-regulation of myosin IIB heavy chain (MYH10) in the 
contractile ring by RUNX1 (Eto & Kunishima, 2016; Okada et al., 2013). Further 
membrane changes get altered and cytokinesis blocked by down-regulation of the 
microtubule-associated guanine nucleotide exchange factor (GEF-H1) and epithelial 
cell–transforming sequence 2 (ECT2), which modulated RhoA activity in the cell 
membrane. RhoA is an enzyme that induces the synthesis of guanine triphosphate (GTP) 
from guanine diphosphate (GDP) and is determinant in cytokinesis, since it induces 
cytoskeleton rearrangement and myosin activity (Gao et al., 2012) (Figure 5). 
 
 
 
Figure 2. Current murine model of HSC differentiation. From top to bottom, HSCs are divided into LT-
HSC and ST-HSC subsets, according to their capacity for self-renewal. Identification of both subsets is 
determined by their expression of LSK, CD34 and Flt3. LT-HSCs are shown as the most primitive 
progenitor, with the potential to give rise to all different lineages in 5 stages of differentiation.  
 
The final purpose of MKs is the production of platelets through a process called 
thrombopoiesis. Endomitosis outcome are MKs with a high ploidy, that will develop 
pseudopods, cytoplasmatic extensions known as proplatelets. Granules containing RNA 
and organelles as mitochondria move to the end of the pseudopods that extend to vessels, 
where circulation finally detach platelets into the bloodstream (Deutsch & Tomer, 2006). 
Thrombopoietin (TPO), which is produced in the liver by hepatocytes as a 
consequence of IL-6 stimulation and in the stromal cells of the bone, help in development 
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of MKs. In normal conditions, it seems that TPO levels keep a steady production. The 
concentration in plasma would be affected by the amount of platelets and MKs, which 
consumes TPO through c-Mpl receptors. Therefore, a high amount of platelets implies a 
low level of TPO and less MKs differentiation. On the other hand, a low amount of 
platelets would imply less consumption of TPO and more induction of MKs 
differentiation (Grozovsky, Giannini, Falet, & Hoffmeister, 2015). Nevertheless, this 
model has not been fully characterized and accepted since it fails to predict the evolution 
of certain pathologies, such as ITP. Kosugi and col., demonstrated that concentration of 
TPO in ITP patients was only mildly elevated in 70% of the cases. In 30% of the patients 
the levels of TPO were equal to healthy controls (Kosugi et al., 1996).  
 
 
 
 
 
Figure 3. Transcription factors involved in final stages of MKP differentiation. MEP predilection to 
differentiate into erythroid progenitor or MKP will translate to a well described dynamic of transcriptional 
factors. MKPs will require inhibition of KLF-1 by RUNX-1, upregulation of FLI-1 and activation of DLX4 
gene, with subsequent NF-κβ expression and IL-1β stimulation. 
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Figure 4. Megakaryocyte developmental pathway (Attar, 2014; Tomer & Harker, 1996). Six surface 
markers, that help identify specific developmental stages, have been represented in the figure. Continuous 
line represent expression on whole population. Discontinuous line implies uneven presence of the specific 
marker. Time points (Day 0, 3, 5, 7 and 10) have been proposed under laboratory conditions, nevertheless, 
it should not be considered as representation of normal physiological development. The loss of expression 
of MHC II in MKP has not been described in detail before, thus the exact moment it disappears cannot be 
represented. A mature MK should express CD38, CD41, CD42b and CD110 in its surface.  
 
 
 
 
 
Figure 5. MKs endomitosis. Figure A, shows the action of ECT2 and GEF-H1 on RhoA in anaphase cell 
cycle, for development of the contractile ring and posterior formation of a cleavage furrow in telophase. 
Figure B, represents the differences of this process in MK maturation. Gao et al, demonstrated a 
downregulation of ECT2 and GEF-H1, leading to restriction of cell division and promoting 
polyploidization in MKs. 
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I.2. Immune Thrombocytopenia (ITP) 
 
I.2.1 Overview 
 
ITP is a condition characterized by the significant reduction of platelets. Although 
considered to be an autoimmune disease, there is no clear evidence of a specific cause in 
all patients. In the overall population, the incidence of ITP is 4/100000 and the prevalence 
is around 24/100000. (Provan & Newland, 2015; Schoonen et al., 2009) with a higher 
incidence in women. Otherwise there is no clear characterisation of a vulnerable 
population for ITP. Additionally, the lack of evidence for the cause of ITP makes it 
difficult to build a model of the disorder, and can even lead us to think that we are facing 
more than one disease with thrombocytopenia as the end result of a number of different 
pathologies. The significant reduction of platelets seen in patients with ITP is related to 
an increased risk of bleeding (Provan & Newland, 2015; Provan et al., 2010; Rodeghiero 
et al., 2009) although the severity of the bleeding is rarely lethal (Portielje, 2001). 
  
I.2.2 Diagnosis  
 
The diagnosis of ITP is mainly based on the clinical history and the decrease of 
platelet count below 100 x 109/L in peripheral blood in the absence of an evident cause. 
Presence of self-antibodies are not considered in the diagnostic criteria since 30 -40% of 
ITP patients do not show positivity in antibodies assays. Also, it has been shown that 
autoantibodies can be identified in cases of non-immune thrombocytopenia, giving a 
specificity of 87.5% (R McMillan, Wang, & Tani, 2003; Provan et al., 2010).  
 
I.3 Immunological abnormalities in ITP 
 
I.3.1 Overview 
 
Current understanding of ITP pathogenesis is commonly characterized by 
peripheral tolerance defects, differentiation blocks with skewed peripheral B-cell subsets 
and central tolerance defects (Kistangari & McCrae, 2013). The break of tolerance leads 
in some patients to production of autoantibodies (IgG) that target GPIIIa/IIb and GPIb/IX. 
These glycoproteins are present in the membrane of MKs and of platelets that are 
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endocytosed by macrophages in the spleen and liver, via fraction crystallisable gamma 
receptors (FcγR). (Kistangari & McCrae, 2013; McCrae, 2011; Toltl, Nazi, Jafari, & 
Arnold, 2011). However, some abnormalities in T cells and MKs development have been 
established (X. Ji, Zhang, Peng, & Hou, 2014). Also, a new mechanism has been recently 
described, involving a dysregulation of sialic acid in platelets surface, has been suggested 
as a contributing factor (Shao et al., 2014).  
 
I.3.2 B-cells 
 
B cells obtain tolerance for self-antigens in the bone marrow. Immature B cells, 
expressing immunoglobulin M (IgM) B cell receptor (BCR) get exposed to self-antigens 
and, in case of reactivity, most of them will get eliminated from the pool of immune cells. 
Under normal circumstances 55 - 75% of immature B cells will show specificity for self-
antigens. This percentage will drop to 20 - 40% in transitional and mature B cells (Pelanda 
& Torres, 2012). The regulatory mechanisms involved in the inhibition of these cells are 
broad and include cell deletion and receptor editing. (Toltl et al., 2011). 
 
Cell deletion is triggered when a B cell shows affinity to self-antigen. This process 
requires the active role of Bcl-2 molecule and the downregulation of two growth factor: 
B-cell activating factor (BAFF) and of a proliferation-inducing ligand (APRIL). In ITP, 
evidence of upregulation of both B cells growth factors has been shown (Emmerich et al., 
2007; Gu et al., 2009).  
 
Continuous receptor editing in B-cells, operates as a safety mechanism to prevent 
persistence of self-reactive immune cells. In that respect, some studies were performed to 
elucidate VDJ recombination characteristics in ITP patients. Although, it has been 
established that there is an overexpression of VH6 gene, it has not been associated directly 
with ITP pathogenesis (van Dijk-Hard, Feld, Holmberg, & Lundkvist, 1999). 
 
The production of specific autoantibodies implies the activation of particular 
mechanisms of the immune system as germinal centre formation, somatic recombination 
and class switch of B-cells. Moreover, it has been suggested that it is a driven by specific 
antigen stimulus. Roark et al. presented several antibodies’ features to support this claim, 
which included a single heavy chain VHDJH rearrangement, high replacement to silent 
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ratio, and platelets reactive fragment antigen-binding (Fabs) that originated from IgG 
library. These evidences imply derivation from a single B-cell and isotype switching 
(Roark, Bussel, Cines, & Siegel, 2002).  
 
Despite, the evidence of B-cells involvement in ITP pathogenesis, there are a lot 
of gaps to clarify. 30 to 40 % of patients do not have anti-platelets’ antibodies (Robert 
McMillan, 2003). Also, whether B-cells disorder is a starting point or a consequence of 
something else, is still a matter of debate. 
 
I.3.3 T-cells 
 
The tendency for CD4+ Th0 - Th1 cells cytokines in ITP patients, is evidence of 
cellular immunity involvement. Patients with chronic ITP show a significant increase of 
IL-2, interferon gamma (IFN-γ) and Tumour Necrosis Factor beta (TNF-β) (X. Ji et al., 
2014; Kuwana & Ikeda, 2005; J W Semple, 2013; Toltl et al., 2011). Furthermore, clear 
evidence has been established of an increased Th1/Th2 ratio (Cooper & Bussel, 2006; 
Robert McMillan, 2007). 
 
CD4+ CTLs is a small subset of T cells with capacity to produce cytotoxicity 
through the release of granzymes and perforines, characteristics mainly associated to 
CD8+ T cells. CD4+ CTLs represent around 2% of all T cells in humans, and their role is 
usually associated to immune response against viral infections that affect antigen 
presenting cells (APCs) (Appay, 2004; Marshall & Swain, 2011). Nevertheless, some 
evidence suggests more plasticity from these cells activity, showing capacity to act 
against cancer cells. Furthermore, Quezada et al. showed that the blockage of the CTLA-
4 molecule boosts CD4+ CTLs expansion (Quezada et al., 2010). This detail becomes 
relevant for ITP studies since it has been showed that it produces a decreased level of 
CTLA-4 (Zhu et al., 2015).  
 
Ye et al. revealed a significant role of a pathway composed by IL-23 and Th17 
cells studying 30 cases of acute ITP. IL-23 has a pro-inflammatory activity and is closely 
related to IL-12. An increased expression of IL-23, IL-17 and of receptors for IL-23 (IL-
23R / IL-12Rβ1) were detected. Th17 is a subset of T-cells that has pro-inflammatory 
functions and their increased presence in ITP patients correlated to IL-23. Finally, the 
 17 
authors suggested that a boost of Th17 activity might be important in the pathogenesis of 
ITP. (Ye et al. 2015). These findings were supporting the previous data reported by Ji et 
al. (L. Ji et al., 2012) that showed a decrease in Treg/Th17 ratio in ITP patients. Treg are 
cells that induce immune tolerance and are strongly related to the prevention of 
autoimmune diseases. The decrease of Treg was further studied Catani et al. finding 
downregulation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase 1 
(IDO1) in DCs (Catani et al., 2013). 
 
T-cell activation is a complex process that requires multiple conditions to be 
fulfilled to happen. It is mainly triggered by the break of balance of multiple activation 
and inhibitory signals. For example, CD8+ T cells’ killing activity will require 
presentation of antigen by the major histocompatibility complex (MHC) class I to TCR 
and the binding of CD8 with MHC class I α3 domain (Belyakov et al., 2007), which is 
considered as signal 1 in a three signals requirement. Signal 2 is established by the 
stimulation of CD28 by CD80 and CD86 (Ertelt et al., 2013). Finally, the presence of 
specific cytokines such as INF-γ will be signal 3. Additionally, to the activation triad, 
inhibitory receptors as CTL-associated antigen 4 (CTLA-4) molecule (Tivol et al., 1995) 
or Programmed Death-1 receptor (PD-1) in the surface of T-cells need to decrease their 
intracellular signaling (M E Keir, Butte, Freeman, & Sharpe, 2008). In the case of CD8+ 
T cells, dynamics and activation has not been studied in detail in ITP patients.  
 
Olsson et al. showed that there is an increase of CD8+ T cells in peripheral blood 
and that that these cells would be primed against platelets and MKs in ITP patients. 
Furthermore, they presented data about immunosuppressive treatment inhibiting their 
killing activity (Olsson et al., 2003). 
 
Whether we consider CD4+ or CD8+ T cells as important in ITP, MHC molecules 
will require to present an antigen to produce activation (Schmidt, Dojcinovic, Guillaume, 
& Luescher, 2013). Studies about this subject in ITP patients are limited. Although, some 
have suggested no relationship between specific MHC alleles and ITP (Gaiger, 
Neumeister, Heinzl, Pabinger, & Panzer, 1994), others consider plausible a disturbance 
in MHC presentation due to cytokines’ effect (Chanock, 2003). 
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I.3.4 Inhibition of megakaryopoiesis in ITP  
 
Although, antibodies against gpIIb/IIIa and gpIb/IX role has been considered as 
platelet targeting exclusively, some data has been shown suggesting an effect on normal 
MK’s function. Chang et al, tested healthy donor’s plasma and ITP patients’ plasma, with 
evidence of anti-platelets antibodies, on MKs. The authors concluded that antibodies 
presence produces an inhibition of megakaryopoiesis (Chang et al., 2003). Other studies 
would support these conclusions (Robert McMillan, Wang, Tomer, Nichol, & Pistillo, 
2004). 
 
Although, several pieces of data reveal a complex disease that dysregulate most 
components of the immune system, there is no definitive aetiology or model of 
pathogenesis established. Figure 6 shows a scheme of the current knowledge about ITP. 
 
I.4 Current treatments 
 
Most treatment strategies have been targeted to inhibit immune mediated 
destruction of platelets. Immunosuppression is achieved through the use of corticoid 
steroids. Intravenous immunoglobulins (IVIg) and anti-D work by saturating Fc 
receptors, blocking endocitosis by macrophages and allowing platelets covered by 
antibodies to stay in circulation. Treatment with IVIg has been associated with decrease 
of IL-12, maturation of DCs and increase of IL-10 (Provan & Newland, 2015). Generally, 
these schemes provide remission in 80% of patients with ITP (Cooper, 2009).  
 
Second line treatments include Rituximab and thrombopoietin receptor agonists 
(TRAs) (Neunert, Lim, & Crowther, 2011). Rituximab, a chimeric monoclonal antibody 
against B cell CD20, aims to decrease the number of plasma cells and, therefore, to 
deplete the manufacturing kit of autoantibodies. Treatment with Rituximab has shown 
increased Treg activity in responders and normalization of other T-cell subsets’ activity 
(Stasi et al., 2008). Nevertheless, only 50-60% of patients respond to treatment and long 
lasting effects seems to be restricted to a third of the cases and due to safety issues there 
is still much discussion about the suitability of this treatment (Arnold et al., 2007). On 
the other hand, TRAs have appeared in the scene as a treatment alternative. Romiplostim 
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and eltrombopag induce megakaryopoiesis and increase the production of platelets to 
compensate the peripheral depletion. TRAs mimic the activity of TPO, which by 
stimulation of the receptor c-MPL in the surface of HSC triggers the differentiation to 
MKs (Imbach & Crowther, 2011). 
 
I.5 Programmed death ligand 1/Programmed death receptor 1 (PD–L1/PD-1) 
 
PD-L1 and PD-1 have been established as regulatory molecules for central and 
peripheral tolerance (Al-Chaqmaqchi et al., 2013; D’Addio et al., 2011; M E Keir et al., 
2008; L. Wang et al., 2008). Their expression in the thymus proved to be important in 
shaping T-cells maturation and selection (Mary E Keir, Latchman, Freeman, & Sharpe, 
2005). Furthermore, they are protagonists in T-cell function (S. Wang et al., 2003).  
 
The binding of PD-1 by PD-L1 induces the blockage of phosphoinositide 3-kinase 
(PI3K), and subsequently, to the decrease cytokines production. The cytokines mainly 
involved in this pathway are IL-2, INF-γ and cell survival proteins like Bcl- xL (M E Keir 
et al., 2008) (Figure 7). Although, stimulation of PD-1 outcome seems to be clear in T-
cell function, the discovery of PD-L1 reverse signaling leaves a broader field to explore. 
Binding of PD-L1 has been proved to inhibit DCs activation and production of IL-10 
(Kuipers et al., 2006). PD-L1 has been showed to be expressed in T cells, DCs, 
monocytes, lung, vascular endothelium, liver, keratinocytes and placental 
synctiotrophoblasts, however, there is a lot of data missing from other tissues (M E Keir 
et al., 2008). Since there is no published data for the expression of PD-L1 in MKs or 
platelets, it is relevant to search for its expression and possible role in pathogenesis. 
 
I.6 HLA-DR expression in ITP 
 
Expression of HLA-DR in HSCs has been clearly shown in previous studies. 
However, changes of HLA-DR expression across MK differentiation lacks more detailed 
description. Previous studies showed persistence of HLA-DR expression in 
megakaryoblasts in patients with increased proliferation of this cell lineage. The high 
heterogeneity of surface markers profile was associated to different stages of 
differentiation and suggested that HLA-DR can be expressed until megakaryoblasts phase 
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(Dent & Berkowitz, 1987). Nevertheless, results from other experiments would propose 
the total loss of MHC class II expression at earlier stages (Tomer, 2004).  
 
In the case of ITP, data is quite limited and sometimes contradictory. Gaiger et al. 
studied the role of HLA-DR and –DP in adult thrombocytopenia, finding no association 
(Gaiger et al., 1994). On the other hand, Semple et al. reported increased expression of 
HLA-DR in ITP patients, without linking it directly to the disease pathogenesis, but 
considering an effect of a subjacent cause (John W. Semple & Freedman, 1995). 
Nevertheless, further data is required to establish the real role of HLA-DR abnormalities 
in ITP. 
 
My research will focus on establishing a model of megakaryopoiesis and platelet 
development. Initial studies will explore the expression of PDL-1 and MHC class II over 
time to add to the literature of surface expression and to define for the first time the 
potential for interactions of T cells with MKs and platelets. Second, the impact of healthy 
and ITP plasma on megakaryopoiesis and platelet production and expression of immune 
surface markers will be explored. 
 
I.7 Hypothesis and aims 
 
Hypothesis 
Megakaryopoiesis is compromised in patients with ITP, contributing to 
thrombocytopenia. Development of a model of megakaryopoiesis will allow examination 
of the potential for MKs to interact with immune cells and allow exploration of the impact 
of healthy and patient plasma on these features. 
 
General aim 
To determine whether plasma of ITP patients alters characteristics of 
megakaryopoiesis including terminal development and expression of immune markers 
including PD-L1 and HLA-DR. 
 
Specific aims 
1. To provide an experimental model to evaluate megakaryopoiesis by 
differentiating CD34+ HSC into MKs. 
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2. To establish for the first time expression of PDL-1 and HLA-DR over time in 
megakaryopoiesis in standard media conditions. 
3. To describe the effect of ITP plasma on MK development and immune surface 
make
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Figure 6. Current knowledge of 
ITP pathogenesis. Scientific 
literature presents multiple gaps in 
ITP’s pathogenesis. Currently there 
is no accepted aetiology or 
hypothetic model.  Nevertheless, 
compromise of central and 
peripheral tolerance has been 
proven, although the mechanisms 
behind them are still a mystery. 
Thymus involvement is still to be 
studied, nevertheless, self-reactivity 
of T cells certainly implies a 
maturation disorder in this subset of 
immune cells.   The dynamics of T 
cells and B cells in bone marrow is 
also a subject without proper 
understanding. Whether there is a 
developmental failure in MKs is 
also a matter that has not been 
studied in detailed.       
For many years it has been known 
that there is a loss of tolerance that 
triggers in most ITP patients’ 
production of antibodies against 
platelets’ surface markers. These 
antibodies start a predictable 
sequence of immune events that 
involve endocytosis of platelets and 
activation of macrophages, 
production of cytokines and 
maturation of different subsets of T 
lymphocytes. There is contradictory 
data about the cytokines involved in 
ITP, but it is generally accepted that 
it has a tendency for a Th1 profile.
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Figure 7. Model of immunological synapse between MKs and T cells. Three activation signals are 
required for T cells activation. These triad is composed by the binding of MHC molecule with TCR, 
CD80/86 with CD28 and the cytokines stimuli. In the absence of a strong MHC signal, cell inhibition can 
be induced by stimulation of PD-1 by PD-L1, which blocks PI3K and further cytokines production. 
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Chapter II. Materials and method 
 
II.1 Cells and culture 
 
II.1.1 HSC cells 
 
HSC Cells were obtained from Hammersmith Hospital’s Stem Cell bank. CD34+ 
cells were separated from the bone marrow of a healthy donor using magnetic beads. 
Cells were counted using a hemocytometer (Marienfeld, Germany) and stored in (10% 
Dimethyl Sulfoxide ((DMSO; Sigma-Aldrich, UK)  + 90% Foetal Bovine Serum (FBS)) 
at a concentration of 12 x 106 cell/mL and stored in the -80°C freezer in the Centre for 
Haematology at Imperial College London, Hammersmith Campus. For thawing and 
revitalisation of cells, vials were opened and 1mL of warm PBS was added into the vial 
and thawed content was taken into a 15mL falcon tube with 10mL of PBS. Cells were 
centrifuged at 1600rpm for 5min, supernatant eliminated and re-suspended in 10mL of 
PBS to repeat a second wash and, then re-suspended in culture medium.  
 
II.1.2 Medium 
 
Cells were cultured in StemSpanTM SFEM II (STEMCELLTM Technologies, 
Cambridge, UK), and supplemented with StemSpanTM Megakaryocyte expansion 
supplement (STEMCELLTM Technologies), according to manufacturers’ instructions. 
Additionally, TPO (Fisher Scientific, Loughborough, UK) was added at a concentration 
of 50ng/mL and 1µL of IL-1β (Fisher Scientific). Medium was filtered with a 0.2µm pore 
syringe filter to prevent any possible contamination. Cells were cultured at a 
concentration of 5 x 105 cells per mL in a 50mL flask and incubated at 37°C and 5% CO2. 
Culture medium was renewed at day 5 and 7.  
 
II.1.3 Plate seeding  
 
At day 7, 3 x 105 cells per well in 24 wells plates. Cells were we-suspended in 
400µL of medium and 100µL of plasma according to established condition (Figure 8). 
Cells cultured in medium only were re-suspended in 500µL. Remaining wells were filled 
with PBS to provide sufficient humidity. Cells were cultured at 37°C and 5% CO2 for 
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additional three days before the they were harvested and analysed.  
 
 
Figure 8. Cells plating and conditions. The three plates show the distribution of different conditions of 
culture. The top plate shows the cells cultured with plasma of 2 patients, one newly diagnosed, and the 
other a chronic patient. In both cases none of them were receiving medication. In the middle plate, cells 
were exposed to plasma of a chronic patient at two different time points: before starting treatment with 
TRAs and after showing platelets count improvement. The bottom plate, shows the plating of cells for 
testing plasma of a chronic ITP patient before and after treatment with Rituximab. Finally, in every plate, 
1 well was used to test plasma of a healthy donor and another well for medium only control. 
 
 
II.2 Patients’ characterisation and Ethics 
 
Patients’ characterisation 
4 patients with diagnosis of ITP, which are being followed at the Haematology 
service of Hammersmith’s Hospital, were selected. Figure 9. 
 
The criteria used for the selection of patients was based in 3 specific points: 
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1. Availability of sample. 
2. Good quality of plasma. 
3. Response to treatment shown by increased platelets. 
 
Figure 9. Patients characteristics. The figure shows some characteristics of the selected patients 
according to diagnosis, and treatment. Additionally, it provides some demographic information as gender, 
age, and platelets count at the time the sample was taken. 
 
Ethics 
Imperial College Tissue Bank granted approval to the study (REC Wales approval: 
12/WA/0196 R12033). Tissue bank consent form was applied to get written informed 
consent from participants. 
 
II.3 Flow cytometric analysis 
 
II.3.1 Sample staining and flow cytometry analysis  
The selection of fluorochromes was determined in light of the commercially 
available options and instrument configuration; lasers and detectors. A multi-colour panel 
of 8 primary conjugated antibodies (as defined in Table 2) was used to study MK 
differentiation process; CD3 (dump channel), CD34, CD38, CD41, CD42b, CD274 and 
HLA-DR. Live cell discrimination was achieved using Live/Dead Fixable Aqua (Fisher 
Scientific). 
 
Live/Dead (Fisher Scientific) staining with performed by adding 0.5µL per 
sample, including both Fluorescence Minus One (FMO) controls and fully stained cells, 
diluted in 1 ml of PBS. Cells were incubated for 20 to 30min in the dark at 4°C and then 
washed and re-suspended with 100µL of PBS for Fc blocking. 
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For Fc blocking, to prevent non-specific binding, 2.5µL of Human Fc Block (BD 
Bioscience) was added to re-suspended cells and incubated for 10min in the dark at room 
temperature. One further wash in PBS was performed at 1600 rpm for 5min. 
 
To stain, roughly 3 x 105 cells were prepared in 100 µL of PBS in separate FACS 
tubes. A master mix of antibody cocktail was calculated so that each sample is stained 
with, 1µL of anti-CD3, anti-CD34, anti-CD38, anti-CD41, anti-CD42b, antiHLA-DR and 
2µL of anti-CD274. Samples were incubated with the master mix in the dark at 4°C for 
20min. Then, cells were washed and re-suspended in 400µL of PBS ready for analysis. 
 
Unstained control, FMO controls were included with each experimental run to 
allow for compensation and determine negative quadrants, respectively. To compensate 
for potential spectral overlap between the neighbouring channels, single stained 
compensation beads BDTM CompBeads Set (BD Bioscience, USA) was included for each 
antibody with the exception of the L/D single stained control that was prepared by mixing 
cooled killed cells (by boiling in a water bath) with unstained live cells and stained with 
LD reagent as detailed above.  
 
Before acquisition, PMT values were adjusted using unstained control to restrain the 
negative population typically below 102 log. Single-stained controls were then acquired at 
5000 events (by default) per tube. The automated compensation matrix of acquired control 
tubes was computed using FACSDiva; no post acquisition compensation was required.  
 
Data acquisition was undertaken on FACSAria II (BD Bioscience) with 3 lasers 
system (Violet 407 nm, Blue 488 nm and Red 633nm) in the BRC core facility laboratory 
housed at the Common Wealth Building, Imperial College London. Table 4 shows the 
settings for the channels’ filters established for fluorescence detection. 
 
Data analysis was subsequently performed using FlowJo v. 8.7, Treestar flow 
cytometry analysis software. 
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II.4 Confocal Microscopy 
 
To detect the surface expression of PD-L1 at day 3, day 7 and day 10, slides were 
prepared with cytospinning, stained cells on glass slides and mount with FluoroshieldTM 
with 4',6-diamidino-2-phenylindole (DAPI; (Sigma-Aldrich, USA), and visualised using 
an inverted Zeiss LSM-780 confocal microscope (Zeiss, Oberkochen, Germany), and Zen 
Lite Software (Zeiss). Further, analysis and edition was fulfilled with FIJI (Schindelin et 
al., 2012) 
 
 
 
Table 2. Antibodies and reagents used for staining 
 
Antibody	 Description	 Fluorochrome	 Company	
CD3	 Mouse	Anti-Human	 V450	 BD	Bioscience	
CD34	 Mouse	Anti-Human	 PECy7	 eBioscience,	UK	
CD38	 Mouse	Anti-Human	 AlexaFluor	700	 Biolegend,	UK	
CD41	 Mouse	Anti-Human	 APC	 Biolegend	
CD42b	 Mouse	Anti-Human	 PE	 eBioscience	
CD274	 Mouse	Anti-Human	 FITC	 AbD	Serotec	
HLA-DR	 Mouse	Anti-Human	 PerCP	 Biolegend	
Live/Dead	 	 Fixable	Aqua	 Fisher	Scientific	
 
 
 
II.5 Statistical analysis 
 
 All data are expressed as mean ± SD unless indicated otherwise. Statistical 
comparison between two groups was carried out using unpaired t tests, using Prism 7.0 
for MacOS X (GraphPad Software Inc, USA). Results were considered statistically 
significant when p<0.05. 
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Table 3. FACSAria II Filters according to specific fluorochrome 
 
Fluorochrome Filter 
V450 450/40V 
Fixable Aqua 
(L/D) 525/50V 
FITC 525/50 
PE 575/25 
PerCP 670/14 
PECy7 780/60 
APC 670/14R 
AlexaFluor 700 710/50R 
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Chapter III. Results 
 
III.1 Gating strategy  
 
Gating strategy for flow cytometry analysis was established as shown in Figure 
10. Side-light- Scattered SSC-A) vs Forward-light-Scattered (FSC-A) was used to gate 
the population of interest. The exclusion of dead cells and elimination of doublets was 
performed by first gating out L/D+ cell population and then FSC-W high cells on serial 
bivariate dot plots (LD vs FSC-A) and then (FSC-W vs FSC-A), respectively. Finally, we 
proceeded to exclude cells expressing surface CD3. 
 
 
Figure 10. Gating strategy for developing MKs. A. FSC-A vs SSC-A. B. Gating for alive cells. C. FSC-
A vs FSC-W, gating of single cells. D. CD34 – PECy7 vs CD3 – V450 for exclusion of cells expressing 
CD3 in its surface. 
 
III.2 Effect of post staining cell fixation on PE signal   
 
Cell fixation with CellFIX (BD Bioscience, UK) post sample staining used 
normally to allow for later acquisition led to a significant upward displacement of PE 
negative population of PE negative control (PE-FMO) causing an overlap with and loss 
of PE positive events in the fully stained samples (Figure 11). This effect was not 
observed on any of the other fluorochromes used. Fresh, unfixed, cells showed the 
expected separation between PE, PE-FMO and fully stained tube containing PE+ cell 
populations (Figure 11). It has been therefore decided to run all samples freshly within 
24 hours of sample staining.   
 
III.3 Optimization of negative controls  
 
Unstained control with FMO for PerCP, FITC and PE were compared to 
determine the optimal negative controls to accurately discriminate positive versus 
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negative signals and draw gates. Whilst there was no signal difference between unstained 
control, FITC-FMO and PE-FMO,  PerCP-FMO showed considerable positive signal 
shift of PerCP- population. As it is shown in (Figure 12 B), PerCP FMO was more 
representative of negative controls than unstained control. PerCP- FMO was therefore 
used to determine PerCP negative and positive events in subsequent analysis.  
 
 
Figure 11. Fixation of cells alters fluorescence profile. Analysis PE-FMO (red) and fully stained (blue) 
MKP on day 7. 
 
 
Figure 12. Fluorescence for FITC and PerCP in unstained (red), FMO (blue) and fully stained (green) 
cells. MKP on day 3 stained with full panel. A. Displays of fluorescence detected by FITC channel. B. 
Displays the fluorescence detected by the HLA-DR channel.  
 
III.4  MK culture and development 
 
The outcome of MKs’ culture optimisation showed appropriate production of 
mature MKs. Using MK culture procedures explained in material and methods section 
II.1.2. Cultured CD34+ HSC started to express one of the earlier MK marker CD41, 
continuing to increase significantly throughout MK development from around 18% on 
day 3 reaching over 90% on day 10. CD42b expression starts to appear as early as day 3 
and continues to rise up as its dual expression with CD41 is a marker of mature MK 
(Figure 14A).  
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Figure 14. MK development and 10 days. A. Displays the increasing expression of CD4 and CD42b over 
time, showing displacement of the whole population towards a double positivity which is a marker of 
mature MK. B. Displays the novel finding of HLA-DR expression during the course of MK development, 
overall decrease across the developing cells. C. Shows PD-L1 expression in relation to CD41which shows 
increase through MK differentiation. Images show CD41+ preceding the expression of PD-L1. 
 
 
Early progenitor cells highly express HLA-DR, which sums up to over 97% on 
day 3. Following the development of the cells a significant reduction is observed 
throughout the culture ending around 63% on day 10 (Figure 14B). The expression of the 
inhibitory marker PD-L1 seemed to be exclusive to CD41+ cells and also to follow its 
progression as it increases through the development of MK from 11% on day 5 to 35% 
on day 10 (Figure 14C). 
 
 
III.5 MK development and expression of surface markers culture in replicates 
 
Culture replicates at day 10 showed expression of CD41 in medium reached a 
mean average of 13.19% (SD±6.83). CD42b+CD41+ cells only represented 0.27% 
(SD±0.23). Loss of CD34 expression reached 11.42% (SD±7.99) (Figure 15). 
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Figure 15. Number of cells (medium only) expressing CD34 and CD41 across development. A. Day 3, 
B. Day 7, C. Day 10. Dot plot showing expression of CD34 and CD41 (left). Photographs (40X) of cells 
showing phenotypic changes (white arrows). (right). D. Line graph showing loss of expression of CD34. 
E. Line graph showing variation in cell number expressing CD41.   
 
III.6 MK differentiation is enhanced in the presence of healthy control and ITP 
plasma  
 
Cells exposed to plasma (Healthy control and ITP) showed an increased the 
overall expression of CD41 as well the percentage of the terminally differentiated 
CD41+CD42b+CD38+ cells.  
 
Expression of CD41 with plasma of a healthy donor ascended to 45.98% 
(SD±10.23) and with plasma from ITP patients to 28.29% (SD±13.94), compared to 
13.19% in medium only. The development of mature MK cells increased significantly to 
36.1% (SD±7.40) in the presence of ITP plasma compared to medium only, 14.3% (P 
value <0.05). Healthy donor’s plasma also had a similar increasing effect but it did not 
reach a statistical significance when compared to medium only (Figure 16).  
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Figure 16. CD41+CD42b+CD38+MK maturation cultured in medium only, plasma of a healthy 
control or ITP patients. The graph shows an overall increase when cultured with plasma from either a 
healthy donor or an ITP patient compared to medium only. It also shows a significant increase in the 
development of mature MK when cultured with ITP plasma compared to medium only. * P value <0.05 
 
 
 
 
 
III.7 HLA expression is maintained in the presence of ITP patient plasma 
 
During MK development, the expression of HLA-DR was found to be decreasing 
as the cells differentiate when left in medium only. Culturing the cells with plasma from 
a healthy donor further reduced the expression of HLA-DR significantly to 53.2% when 
compared to ITP plasma at 75.4%. The difference in HLA-DR expression was not of 
statistical significance between the cells cultured in medium only and with ITP plasma, 
showing positivity in 81.23% and 75.4% of the cells, respectively (Figure 17). 
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Figure 17. HLA expression of cells cultured in medium only, plasma of a healthy control or ITP 
patients. The graph shows an overall decrease when cultured with plasma from either a healthy donor or 
an ITP patient compared to medium only. Major reduction in HLA-DR expression is achieved with healthy 
plasma compared to ITP plasma. * P value <0.05 
 
 
 
 
 
III.8 PD-L1 expression is increased in the presence of healthy control and ITP 
patient plasma 
 
Expression of PD-L1 seemed to be increasing through the development of MK 
reaching 21.13% (SD±16.99) after 10 days in culture medium. An observed rise in the 
expression of PD-L1 when cultured with healthy control plasma and ITP plasma to 
25.06% (SD±19.10) and 17.21% (SD±8.26) respectively (Figure 18)(Figure 19).  
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Figure 18. Expression PD-L1 in cells cultured in medium only, plasma of a healthy control or ITP 
patients. The graph demonstrates an overall increase in PD-L1 expression when cultured with plasma from 
either a healthy donor or an ITP patient for three days compared to medium only. No significant difference 
in expression was observed when cells were cultured with either healthy controls or ITP plasma. 
 
The surface expression of PD-L1 on mature MK was confirmed using confocal 
microscopy which showed distinctive surface expression that differed from both CD41 
and CD42b receptors (Figure 18).  
 
 
 
Figure 19. PD-L1 expression in mature MK. A single mature MK stained captured with different 
channels for each fluorochrome; DAPI (Blue); PD-L1 (Green); CD42b (Red) and CD41 (Yellow). Lower 
middle image represents when all the channels are combined. The distinctive expression of PD-L1 can be 
appreciated in the merged channel where green colour stands by itself not overlapping with any other 
channel, as in the case with CD41 and CD42b appearing orange in some areas in the merged channel. Image 
was captured using an oil lens with X63 magnification.  
 37 
 
Figure 20. Expression of PD-L1 in MKs. A. Day 3, B. Day 7, C. Day 10. Dot plot for CD41 vs CD42b 
(left). Confocal microscopy (right) of stained cells with DAPI (Blue), PD-L1 (Green), CD42b (Red) and 
CD41 (Yellow). Lower middle image represents the merged image. Lower right image shows scale for 
5µm. D. Line graph showing average expression of PD-L1. E. Line graph showing expression of double 
positive cells for CD41 and PD-L1.  
 
Cells were cultured and analysed in ITP plasma of patients post-treatment once 
for Rituximab and TRAs. Expression of surface markers after rituximab treatment 
showed 17.3% of CD34-, 55.8% of CD41+ cells, 6.58% of CD42b+CD41+, 26.9% of 
CD42b+CD41+CD38+, 75.3% of HLA-DR+, 18% of CD41+ HLA-DR-, 8.59% of PD-L1+ 
and 6.35% of CD41+PD-L1+. 
 
Post TRA treatment plasma presented 6.58% of CD34-, 25.2% of CD41+ cells, 
8.44% of CD42b+CD41+, 44.1% of CD42b+CD41+CD38+, 87.5% of HLA-DR+, 4.43% 
of CD41+ HLA-DR-, 17.5% of PD-L1+ and 13.1% of CD41+PD-L1+. 
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Figure 21. Contrast of surface markers expression between cells cultured in medium only and with 
healthy control plasma. Unpaired T-test analysis. Data shown from three different cultures after 10 days 
of differentiation. A. Percentage of cells expressing CD34. B. Percentage of cells expressing CD41 
(p<0.05). C. Percentage of cells CD42b+CD41+. D. Percentage of cells CD42b+CD41+CD38+ (p<0.05). E. 
Percentage of cells expressing HLA-DR (p<0.05). F. Percentage of cells CD41+HLA-DR- (p<0.05). G. 
Percentage of cells expressing PD-L1. H. Percentage of cells CD41+PD-L1+. 
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Figure 22. Contrast of surface markers expression between cells cultured with healthy control plasma 
and ITP plasma without treatment. Unpaired T-test analysis. Data shown from three different cultures 
after 10 days of differentiation. A. Percentage of cells expressing CD34. B. Percentage of cells expressing 
CD41 (p<0.01). C. Percentage of cells CD42b+CD41+. D. Percentage of cells CD42b+CD41+CD38+. E. 
Percentage of cells expressing HLA-DR. F. Percentage of cells CD41+HLA-DR- (p<0.01). G. Percentage 
of cells expressing PD-L1. H. Percentage of cells CD41+PD-L1+. 
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Chapter IV. Discussion 
 
Megakaryocytes (MKs) derive from haematopoietic stem cells (HSCs) by a 
process called megakaryopoiesis (Deutsch & Tomer, 2006). Once a lineage commitment 
has been established, development towards mature MKs will be characterised by DNA 
endoreduplication, cytoplasmic expansion and release of cytoplasmic fragments or 
platelets (Deutsch & Tomer, 2006). The different stages in the development of MKs can 
be described in the following sequence: burst-forming units MKs (BFU-MK), Colony 
forming units MKs (CFU-MK), pro-megakaryoblasts, megakaryoblasts and MKs. The 
evolution across these stages are based in the development of polyploidy, which gets up 
to 128n (Ravid, Lu, Zimmet, & Jones, 2002). For the recognition of these stages, the 
surface expression of glycoproteins is considered a useful tool (Tomer, 2004).  
 
The purpose of these differentiated cells is to produce platelets, which are 
involved in the development of blood clots and wound healing. Immune 
thrombocytopenia (ITP) is defined as a reduction in the platelet count in the absence of a 
clear cause (Kistangari & McCrae, 2013). Although traditionally thought to result from 
increased platelet destruction, impaired megakaryopoiesis is also relevant in ITP. In order 
to understand the reasons for the trigger of the immune system against MKs and platelets, 
we need to know in detail the differentiation process. Although, there is information of 
MKs development in humans, most data about HSCs differentiation into different 
lineages has been the result of murine studies. Hence, data cannot necessarily be 
extrapolated to humans and further modelling of MKs development is required in 
humans. 
 
We have demonstrated MK development in the laboratory. The culture protocol 
showed consistent production of CD42b+CD41+ cells. Also, the progression of surface 
markers expression in time, showed compatibility with the previous data published 
(Tomer, 2004). The efficiency of our protocol for MK differentiation showed some 
variability between different cultures and requires further optimisation. Nonetheless, 
lineage commitment to MK was solidly established. Since there was a recognisable 
increase in the amount of dead cells in latter cultures, efficiency in cell differentiation 
should require a careful study of stored HSCs viability. It has been demonstrated that 
cryopreservation keeps HSCs properties (Fleming & Hubel, 2006; Spurr, Wiggins, 
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Marsden, Lowenthal, & Ragg, 2002), but whether if specific subsets, like MK biased 
HSCs (Bryckaert, Rosa, Denis, & Lenting, 2015), are especially vulnerable or not to 
cryopreservation, is unknown. 
 
The culture of MKs over time also showed a progressive decrease in the 
expression of HLA-DR over time, consistent with published data (REF). The continued 
presence of some HLA-DR positive cells may relate to the early termination of the culture 
(culture to day 12 and production of platelets may result in further decrease in HLA-DR).  
  
The progression of HSCs towards MKS was enhanced with the addition of healthy 
plasma at day 7. There was a significant increase of CD41+ cells and decrease in the 
expression of HLA-DR in cells cultured with healthy plasma. The addition of ITP plasma 
did not show higher expression of CD41+ cells compared to medium, but did show a 
preservation of HLA-DR expression. This resulted in a lower number of CD41+HLA-
DR- cells in cells cultured with ITP plasma compared to those cultured with healthy 
plasma (p<0.05).  
This outcome allows us to state that the addition of plasma at day 7 enhances the 
differentiation of MKs and that plasma can modulate not only the differentiation of MKs, 
but also the expression of surface markers which may result in a different role for these 
MKs. Previous studies suggest megakaryopoiesis is inhibited when cultured with ITP 
plasma, however plasma was added at day 0 in these cultures (Chang et al., 2003; Robert 
McMillan et al., 2004). Further work is clearly required. 
 
The relatively lower CD41+ cells in cells cultured in patient plasma may reflect 
the presence of anti-platelet antibodies or other plasma derived factors. Some studies 
suggest that alterations in MK development are mainly associated to antibodies’ activity 
(Psaila & Bussel, 2007). Nevertheless, 30% of ITP patients lack anti-platelet antibodies. 
It still has to be determined, whether these patients produce different, undiscovered 
antibodies, or if the cytokine profile induces alterations in MK development (Chanock, 
2003). 
 
In respect to HLA-DR expression, previous studies have not shown presence of 
HLA-DR in mature MK. Current literature states that HLA-DR expression is lost in early 
stages of MK development in fresh bone marrow samples (Tomer, 2004). This has not 
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been studied in vitro culture expansion. In our experiment, we showed that healthy plasma 
significantly decreases the expression of HLA-DR compared to ITP plasma. These results 
support a case study that suggests that cytokines in plasma induce HLA-DR expression 
in platelets in patients with ITP (Boshkov, Kelton, & Halloran, 1992). The role of HLA-
DR in ITP pathogenesis has not been settled. Some studies could not link HLA phenotype 
to disease risk and evolution (Gaiger et al., 1994). Whether the phenotypic changes in 
MKs seen with plasma perpetuates the disease or is a consequence of the disease needs 
to be determined.   
 
Although no statistical difference has been proven in the expression of PD-L1, its 
presence has been persistent in several time points, and seems that it is not affected by 
the differentiation process. Analysis of confocal microscopy images confirms the 
presence of PD-L1 in CD42b+CD41+ cells. More studies are needed with an optimised 
culture, but the regularity of PD-L1 expression, even in cells with control and ITP plasma, 
allow us to state that we have shown for the first time the expression of PD-L1 in MKs 
(M E Keir et al., 2008)(Chen & Han, 2015). 
 
No significant differences were obtained with other markers. However, an 
optimised culture should provide a bigger sample for analysis, and additional differences 
cannot be discarded. Nonetheless, we consider that the demonstration of differences 
between healthy control and ITP patients without treatment is a good starting point for 
further research.   
 
To establish the clinical relevance of PD-L1 in ITP more studies will have to be 
carried out. It has been demonstrated that PD-L1 expression is altered by IFN-γ, GM-
CSF, IL-4, IL-12 in multiple cells (Okazaki & Honjo, 2007), which would be relevant to 
ITP pathogenesis. Furthermore, polymorphisms of PD-1 receptor showed association 
with autoimmune diseases such as systemic lupus erythematous (SLE) and multiple 
sclerosis (MS) (M E Keir et al., 2008; Prokunina et al., 2002). Future work should focus 
on the confirmation of HLA-DR and PD-L1 in vivo, which would broaden the view of 
immune regulation with MK as a protagonist.   
 
The tasks developed by MKs can be summarized in the production of two specific 
items: platelets and vWF. Platelets are enucleated structures and owe their properties to 
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MKs. Thus, it has been established that the role of MKs lies in the indirect maintenance 
of tissues and haemostatic regulation. Likewise, recent studies, have shown some 
evidence suggesting a significant role of platelets in host’s defence against infections and 
inflammation (Beaulieu & Freedman, 2010; Duerschmied, Bode, & Ahrens, 2014; Z. Li, 
Yang, Dunn, Gross, & Smyth, 2011). The presence of CD40 ligand (CD40L), TLRs and 
pro-inflammatory and bactericidal molecules like α - granules, dense granules, lysosomes 
and defensins, are proof of platelet’s potential in host defense (John W Semple, Italiano, 
& Freedman, 2011). Furthermore, studies in human diseases like parasitic infections 
(Mcmorran et al., 2009), sepsis (Z. Li et al., 2011), atherosclerosis, metabolic syndrome, 
asthma and ischemia/reperfusion syndrome, have demonstrated a wide response 
versatility, suggesting a higher role than commonly credited. Unfortunately, detailed 
understanding of these functions are still a work in progress (Duerschmied et al., 2014; 
John W Semple et al., 2011). Therefore, we venture to suggest that MK abnormalities 
translate into immunological disturbances that might not necessarily be clinically evident. 
 
Further work will include standardisation of MK culture. Addition of plasma from 
day 0 might allow better differentiation and could show a more differences between 
conditions since cells would be exposed for a longer period of time to distinct cytokines. 
Also, plasma might induce differentiation of other cell lineages giving a more realistic 
depiction of cells development. Additionally, it will be necessary to discriminate effect 
of plasma cytokines from the effect that antibodies might be inducing.  
 
Finally, we can conclude that MKP and mature MK can express PD-L1 in vitro 
culture. Also, healthy plasma and ITP plasma has the potential to enhance the 
differentiation process, as seen by the increased number of mature MK subsets. Cells 
cultured with ITP plasma will express less CD41+ and CD41+HLA-DR- cells than healthy 
controls. The possibility of immune regulatory properties require further investigation.
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